Abstract
Background Whole blood donors are at increased risk for iron deficiency and anaemia. The current standard of haemoglobin (Hb) monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. We determine the effects of ferritin-guided donation intervals for blood donors and the blood supply.
Methods A ferritin-guided donation interval policy was implemented and evaluated through a stepped-wedge cluster-randomised controlled trial in all blood collection centres in the Netherlands. Ferritin was measured in new donors and at every 5th donation. Subsequent donation intervals were extended to six months if ferritin was 15 - 30 ng/mL and to twelve months if ferritin was <15 ng/mL. Primary outcomes are ferritin and Hb levels, iron deficiency, Hb deferral, and donor return. Secondary outcomes are self-reported iron deficiency-related symptoms. Operational statistics assessed the impact on the blood supply.
Findings Among 412,888 whole blood donors, 36,099 were measured. Ferritin-guided intervals increased ferritin levels by 0.24 log10 ng/mL (95% CI 0.22 – 0.27, p <0.001) and Hb by 0.37 g/dL (95% CI 0.31 –0.43, p <0.001). Donors were less likely to be iron deficient (OR 0.15, 95% CI 0.10 – 0.21, p <0.001) or deferred based on Hb (OR 0.23, 95% CI 0.11 – 0.41, p <0.001). However, donors returned less frequently (OR 0.60, 95% CI 0.51 – 0.67, p <0.001), necessitating more invitations and reducing the average donation frequency. No improvement in self-reported symptoms was observed.
Interpretation Ferritin-guided donation intervals significantly improved Hb and ferritin levels, reducing iron deficiency and Hb deferrals. While beneficial for iron and Hb maintenance, efforts are needed to recruit and retain donors and remedy self-reported symptoms.
Funding and registration This project received support from the ’Product and Process Development Cellular Products Grant’ (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee of Sanquin. The trial was registered in the Dutch trial registry (NTR6738) on September 29th, 2017 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NTR6738
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/32998766/
Funding Statement
The current project is supported by the Product and Process Development Cellular Products Grant (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin, Amsterdam, The Netherlands.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Board of Directors, the Medical Advisory Council and Ethics Advisory Council of Sanquin Blood Supply Foundation gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
a.meulenbeld{at}sanquin.nl, s.ramondt{at}vu.nl, m.sweegers{at}nki.nl, f.quee{at}sanquin.nl, f.prinsze{at}sanquin.nl, e.hoogendijk{at}amsterdamumc.nl, dorine.swinkels{at}radboudumc.nl, k.vandenhurk{at}sanquin.nl
This manuscript has been revised to include additional analyses on the impact of the implemented policy on the national blood supply (presented in Table 2). The abstract has been updated to also include these analyses.
Data Availability
The study protocol of the FIND'EM trial including a statistical analysis plan was previously published. Analysis code used to produce the results reported in this article are available online. Individual participant data, after de-identification, that underlie the results reported in this article (text, tables, figures, and appendices) are available to researchers from GDPR compliant institutions, after provision of a methodologically sound and feasible proposal. Requests can be submitted to the authors immediately following publication. A material transfer or research collaboration agreement has to be agreed and signed with the researcher.
